November 18, 2026
Health news, explained with evidence
LIVE

New Risk-Benefit Framework Aims to Accelerate Precision Oncology Trial Enrollment Using Local Biomarker Tests

🔬 Research 1 min read 👁 2

A working group published a risk-based framework in Nature Health Sciences to help sponsors evaluate local biomarker tests for oncology clinical trial enrollment.

🔬Research

Key points

  • Local biomarker testing can accelerate oncology clinical trial enrollment compared to centralized assays.
  • A new risk-based framework helps sponsors manage technical and regulatory complexities.
  • The working group initiative was funded by several major pharmaceutical companies.

A newly published framework detailed in Nature Health Sciences explores how utilizing local clinical site biomarker tests or patient medical records can speed up oncology clinical trial enrollment. Developed by the Local Testing in Clinical Trials Working Group and facilitated by Tapestry Networks, the initiative addresses the operational, technical, and regulatory hurdles that trial sponsors traditionally face when moving away from centralized laboratories.

What to know: While relying on local testing data may help patients enter precision oncology trials more quickly, it introduces several complexities for trial organizers. The working group's proposed risk-benefit structure is designed to guide sponsors in navigating these challenges responsibly, though the approach involves careful validation considerations rather than immediate changes to standard protocols.

The manuscript development was funded by major pharmaceutical companies including Amgen, AstraZeneca, Eli Lilly, and Gilead Sciences, with several authors reporting employment, stock ownership, or affiliations with these firms. Readers should consult qualified healthcare professionals regarding any personal medical decisions or clinical trial options.

Source Nature Health Sciences — nature.com/articles/s41698-026-01765-8 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.